FDA OKs Stem Cell Trial for Spinal Cord Injuries – Drug Discovery & Development
| Drug Discovery & Development The U.S. Food and Drug Administration (FDA) has authorized the StemCells Inc.’s Investigational New Drug (IND) application for clinical testing of the company’s HuCNS-SC human neural stem cells as a treatment for spinal cord injury. As a first action … StemCells, Inc. Announces Pricing of Public Offering to Raise $16.2 MillionWall Street Journal FDA says StemCells can expand clinical trial to USBusinessweek StemCells, Inc. Receives FDA Authorization of IND for Spinal Cord InjuryGlobeNewswire (press release) |
